1.The change of Bax/Bcl-2 on endotoxin-induced acute lung injury
Chinese Journal of Primary Medicine and Pharmacy 2006;0(10):-
Objective To observe the change of Bax/Bcl-2 of pulmonary epithelium on endotoxin-induced acute lung injury.Methods 60 rats were randomly divided into two groups:control group,LPS group.After giving LPS 5mg/kg or NS 4 hours,the respiratory rates and partial pressure of arterial oxygen were measured.Then the rats were killed and the ratios of W/D of lung tissue were detected.The Bcl-2-positive cells and Bax-positive cells were measured by using immunocytochemistry.Results After giving LPS,the respiratory rates and the ratios of W/D of lung tissue were higher than those in control group.Partial pressure of arterial oxygen was lower than that in control group.Bcl-2-positive cells had no significant difference between two groups,and Bax-positive cells were higher than those in control group.Conclusion The increasing of Bax-positive cells induced the apoptosis might be the mechanism of ALI.
2.Double filtration plasmapheresis combined with daclizumab in the treatment for sensitized recipients of cadaver kidney transplantation
Hongfeng HUANG ; Jianghua CHEN ; Jianyong WU
Chinese Journal of Urology 1994;0(02):-
20% ) were assigned to 2 groups according to study intervention: group A ( n =72) receiving DFPP and group B ( n =41) as controls.Group A was subdivided into 2 groups:group A1 ( n =44) was treated by DFPP alone and group A2 ( n =28) was treated by DFPP plus Dac.The incidence rates of HAR,AR,adverse reaction,patie nt/kidney survival,kidney function were observed. All the patients obtained a fo llow-up ≥12 months. Results In 72 patients of group A ,the level of PRA decreased from (60.5?17.7)% to (19.3?11.2)%,with a mean of (41.2?16.9)% ( P 0.05),with 1 kidney-year survival of 94.4% in group A and 78.0 % in group B ( P 0.05);those of AR were 36.4% and 14.3%,respectively ( P 0.05).No difference in infection episodes an d adverse events between group A and PRA-negative recipients, the same as those between group A1 and A2. Conclusions DFPP can decrease the level of PRA significantly before transplantation by selectively eliminating the sensitive antibody,especially when combined with Dac,which can make sensiti zed recipients get the chance of transplanting and further reduce the incidence of AR.The patient/kidney survival rates of 1 year are satisfactory.Being well to lerated by the sensitized patients,treatment of DFPP combined with Dac is safe a nd effective.
3.Combination of 308 nm excimer laser with topical pimecrolimus cream for vitiligo in childhood
Xiaoyan HUANG ; Huilan YANG ; Jianyong FAN ; Xuemei LI
Chinese Journal of Dermatology 2008;41(4):220-222
Objective To assess the efficacy and safety of 308 nm excimer laser plus topical pimeevaluated after 15 and 30 times of laser therapy respectively.ResultsExcept for one patient,all patients were able to be evaluated for effiicacy.After 30 times of laser therapy,the response and excellent response rates were 89.6%and 77.1%respectively,in group A,5.0%and 52.1%respectively in group B;both rates were significantly higher in group A than in group B(both P<0.05).Also,a highler repigmentation rate was obtained in facial lesions in group A compared with group B.Conclusions The 308 nm excimer laser is safe,erective and well-tolerated for vitiligo in childhood,and the combination with topical imecrolimus cream may improve its efficacy in facial vitiligo.
4.Intervention of Ginkgo biloba extract on renal hemodynamics and its clinical protective mechanism
Hongfeng HUANG ; Qian LIANG ; Lan LAN ; Jianyong WU ; Jianghua CHEN
Chinese Journal of Organ Transplantation 2015;36(11):652-656
Objective To observe the effect and safety of Ginkgo biloba extract (EGb) in patients with chronic allograft nephropathy (CAN),and to study the clinical protective mechanism of EGb.Method A prospective,non-randomized,controlled study was conducted on 103 cases of CAN from March 2013 to March 2015.All patients were divided into experimental group (group A,53 cases) and control group (group B,50 cases).The group A was treated with EGb.Patients were followed up for at least 6 months.Before and after treatment,the changes in renal hemodynamic parameters were observed.The biochemical parameters were also observed,including 24-h urinary protein,urinary albumin,serum creatinine (Scr),triglyceride (TG),total cholesterol (TC),estimated glomerular filtration rate (eGFR),platelet count (PLT),fibrinogen (FIB),D-dimer (DD),activated partial thromboplastin time (APTT).The clinical efficacy and safety were analyzed.Result (1) Therewere no significant differences in clinical and biochemical parameters between the two groups before treatment (P>0.05).(2) After treatment,the systolic peak flow velocity (Vmax) of segmental artery and arcuate artery in the experimental group was significantly higher than in the control group,and the resistance index (RI) in the experimental group was significantly lower than that in the control group,P<0.05.(3) In both two groups,the 24-h urinary protein,urinaryalbumin,TG,TC and Scr were decreased after treatment (P<0.05),and eGFR was elevated (P<0.05).Moreover,the changes in 24-h urinary protein and urinary albumin in the experimental group were more significant than the control group after treatment (P<0.05).(3) PLT,FIB and DD in experimental group were significantly decreased after treatment,and APTT was increased significantly (P<0.05).PLT,FIB,DD and APTT had significant change after treatment in the experimental group as compared with control group.(4) There were no significant differences in adverse reactions between two groups (x2 =0.047,P =0.828).Conclusion The therapy of EGb in patients with CAN could reduce urinary protein and improve hypercoagulable state,and had few adverse reaction with good security.
5.Different expression of miRNA-449 a in lung cancer and precancerous tissue
Jianyong LIN ; Yibin DENG ; Yanhong LUO ; Xiaochan LU ; Yongzhi HUANG
Basic & Clinical Medicine 2015;(1):44-47
Objective To investigate the expression and biological function of miRNA-449 a in lung cancer . Methods A case-control study was conducted in 58 patients diagnosed with lung cancer ( carcinoma and adeno-carcinoma) and normal tissue closely adjacent to tumor.MiRNA-449a simulation was designed and synthesized, was dissolved into two different concentrations as 10 and 20 mg/mL.The expression of miRNA-449a in lung cancer tissues and matched normal tissues were detected by Real time PCR .The expression of luciferase gene was detected by chemiluminescence technique.MiRNA-449a mimics on cell apoptosis was evaluated by MTT assay . Results The mean tissues expression levels of miRNA-449 a in squamous carcinoma group and adenocarcinoma group were 1.48 ±1.63 and 1.52 ±1.54 respectively, and were significantly lower than in control group (2.74 ± 1.55 ) ( P<0.01 ) .The average intensity of fluorescent protein in 10 mg/mL group and 20 mg/mL group were 2 115 ±168 and 1 352 ±159 respectively , and were significantly lower than that in control group ( 4 975 ±115 ) ( P<0.01 ) .Conclusions MiRNA-449 a was down-regulated expression in lung cancer and induced apoptosis .
6.Progress of response evaluation and prognosis in chronic lymphocytic leukemia:reports from the 56th American Society of Hematology annual meeting
Ying HUANG ; Lei FAN ; Wei XU ; Jianyong LI
Journal of Leukemia & Lymphoma 2015;24(1):20-22
Chronic lymphocytic leukemia (CLL) is an incurable B cell chronic lymphoproliferative disorder with a highly heterogeneous clinical course.The malignant B lymphocytes that have a mature appearance infiltrate in to lymph node,bone marrow,liver and spleen.The 56th American Society of Hematology (ASH) annual meeting explored multiple aspects including pathogenesis,treatment,response evaluation and prognosis of CLL.Clinical outcome of CLL patients can be predicted more accurately by a series of novel markers such as minimal residual disease.The progress of response evaluation and prognosis in CLL were focused in this review.
7.Long-term effectiveness of anti-interleukin-2 receptor antibodies vs.rabbit antithymocyte globulin as induction therapy in kidney transplantation
Guangjun LIU ; Hongfeng HUANG ; Wenhan PENG ; Jianyong WU ; Yimin WANG ; Jianguo ZHANG ; Jianghua CHEN
Chinese Journal of Organ Transplantation 2012;33(6):331-334
Objective To compare the long-term effectiveness of anti-interleukin-2 receptor antibodies vs.rabbit antithymocyte globulin as induction therapy in kidney transplantation.Methods Between 2006 and 2010,371 recipients of kidney transplants were treated with calcineurin inhibitors (CNI),mycophenolate mofetil and prednisone.261 patients of them received induction therapy with anti-interleukin-2 receptor antibodies (IL2Ra group),and 88 patients received rabbit antithymocyte globulin (rATG group).All the patients received ganciclovir against cytomegalovirus and SMZ against pneumocystis carinii.The data of delayed graft function (DGF),the rate of acute rejectin (AR) and infection in the first year and patient/allograft long survival rate in two groups were retrospectively analyzed during a follow-up period of 1 to 5 years postoperatively.Results There was no significant difference in the sex,age and causes of end-stage renal disease between the two groups.The rATG group had more kidney transplants from deceased donors (P<0.01 ) and the cold ischemia time was longer than that of the IL2Ra group (P<0.01 ).The IL2Ra group and the rATG group had similar incidence of DGF (3.1% vs.1.8%,P>0.05).One year after operation,the incidence of AR in IL2Ra group and rATG group was 10.7% and 2.7% respectively (P<0.05),and the incidence of infection in IL2Ra group and rATG group was 14.9% and 21.8% respectively (P>0.05).One-,two- and three-year patient survival rate in IL2Ra group was 98.9%,98.9% and 98.5% respectively,and that in rATG group was all 98.2% (P>0.05).The one-,two- and three-year allograft survival rate in IL2Ra group was 98.5%,98.1% and 97.7% respectively,and that in rATG group was all 97.3% (P>0.05).Conclusion rATG is more effective than IL2Ra preventing from acute rejection and does not increase the risk of infection for induction in kidney transplant recipients.
8.The Hearing Aids Outcome Associated with Speech Discrimination Abilities in Noise in Presbycusis Patients
Lu PENG ; Ling MEI ; Qin ZHANG ; Jianyong CHEN ; Yun LI ; Yan REN ; Zhiwu HUANG
Journal of Audiology and Speech Pathology 2015;(6):626-629
Objective To investigate the relationship between pure -tone audiometry (PTA ) ,speech dis‐crimination abilities in quiet or in noise and the international outcome inventory for hearing aids (IOI-HA) in pres‐bycusis patients .Methods Twenty presbycusis subjects were tested in this study .Pure-tone audiometry (PTA) and speech discrimination threshold were obtained before being fitted with hearing aids .They weared hearig aids more than six months ,and pure-tone audiometry ,speech discrimination scores in quite(the level = 65 dB SPL) and in noise(signal to noise ratio = 10 dB) were carried out in sound field .A stepwise forward multiple-regression analysis was performed to investigate the impact of PTA and speech discrimination scores to IOI-HA .Results The PTAs before or after hearing aid fittings showed a negative association with IOI-HA ,while speech discrimination scores in quiet or in noise before or after hearing aid fittings showed a positive association with IOI-HA .Speech discrimination threshold in noise was identified as a single predictor of IOI-HA(P<0 .001) .Conclusion The relation between speech discrimination scores in noise and IOI-HA suggests that a poor score might limit the hearing aids outcome .The speech discrimination scores in noise help the clinicians predict the outcomes of hearing aid in real‐ities .
9.Effect of Sorafenib in Increased VEGF in Stimulating Effect of Walker-256 Transplanted Liver Cancer Model in SD Rats
Nan LI ; Bin CHEN ; Yonghui HUANG ; Run LIN ; Haitao DAI ; Keyu TANG ; Jianyong YANG
Journal of Sun Yat-sen University(Medical Sciences) 2017;38(3):364-371
[Objective] To investigate association between the time point of sorafenib administered and suppress effect on tumor growth secondary to the increased expression of vascular endothelial growth factor (VEGF).[Methods] Fifty SD rats were performed intrahepatic implantation using tumor tissues from subcutaneous tumors in nude mice which were administered Walker 256 tumor cells.Ten days after the procedure,MR scans were used to choose forty SD rats with successful hepatic tumor transplantation among fifty experimental animals.Then they were randomly divided into four groups:(A,control group) mere injection of vascular endothelial growth factor (VEGF);(B) administration of sorafenib 72 hours prior to VEGF injection;(C) administration of sorafenib together with VEGF injection;(D) administration of sorafenib 72 hours later to VEGF injection.The tumor growth and median survival time of rodents were observed and compared.After each experimental animal died,immunohistochemical (IHC) methods were applied to detect the expression of VEGF in tumors.[Results] Ten days after the administration of sorafenib,MR showed significant growth of hepatic tumors,the tumor size in experiment group were significiant smaller,than control group (5.4 cm) with statistical significance.Median survival time of four groups were (19.6 ± 1.8) d,(31.2 ± 7.0) d,(27.4 ± 4.9) d,and (26.5 ± 4.6) d,respectively,which indicated that animals in sorafenib groups lived longer than those in control group (P < 0.05).Differences can be obseverd in sorafenib groups with statistical significance existing (P < 0.05).Harvest hepatic tumor tissues from dead animals and HE staining as well as IHC examination were performed.The expression of VEGF in four groups were 88.3 ± 13.6,42.8 ± 8.0,71.9 ± 15.7,and 73.6 ± 13.7.There were statistical significance between control group and sorafenib groups.And further in sorafenib groups,the expressions of VEGF also varied greatly.[Conclusion] Sorafenib can extend the survival time,reduce tumor angiogenesis.And we can conclude that administration of sorafenib before the transient increased expression of VEGF offers survival benefits than that after the evaluation of VEGF levels.
10.Statin-induced rhabdomyolysis in renal transplant recipients: two cases reports
Guangjun LIU ; Jianyong WU ; Yiming WANG ; Hongfeng HUANG ; Wenhan PENG ; Jianguo ZHANG ; Jianghua CHEN
Chinese Journal of Organ Transplantation 2017;38(1):15-17
Objective To discuss the pathogenesis of the statin-induced rhabdomyolysis in renal transplant recipients.Methods We presented two renal transplant recipients who developed rhabdomyolysis in 2012 in our hospital.The clinical presentation,laboratory results,diagnosis and treatment of the two patients were analyzed retrospectively.The basic immunosuppressive agent of two patients was cyclosporine A.The recipients developed rhabdomyolysis following simvastatin lipidlowering therapy,and one patient suffered acute renal failure simultaneously.Acute tubular injury was confirmed by renal biopsy.Finally,the symptoms of the two patients were relieved completely,creatine kinase (CK) returned to normal after the satins discontinued and saline,sodium bicarbonate and diuretics were given.The renal failure patient underwent plasma exchange and CRRT,and the renal function returned to normal.Results The level of cyclosporine A should be monitored when the renal transplant patient was given statins,especially whose basic immunosuppressive agent was cyclosporine A.At the same time we should pay more attention to the symptoms of the myotoxic side effects and avoid using the drug which was also metabolized by CYP3A4.Conclusion Physicians should be aware of the potential risks of combined therapy of statins which are metabolized by P450CYP3A4 and cyclosporine A in transplant patients.If using it is advisable to begin with small dosage and monitor the CK level.